Nitrogen Bonded Directly To A Ring Carbon Of The Purine Ring System (e.g., Guanine, Etc.) Patents (Class 514/263.37)
  • Patent number: 11333667
    Abstract: This patent document discloses techniques, systems, and devices for detecting a target substance using optical nonlinear wave mixing for enhanced detection sensitivity and accuracy. In one aspect, a method for measuring ?-synuclein in a body fluid of a patient with high detection sensitivity and accuracy and providing early stage Parkinson's disease detection is provided. The method may comprise: supplying to a capillary analyte cell a fluidic sample that includes a body fluid of a patient containing ?-synuclein, wherein the capillary analyte cell is located in a nonlinear optical four-wave mixing device; directing laser light from the nonlinear optical four-wave mixing device into the capillary analyte cell to cause nonlinear optical four-wave mixing in the fluidic sample to generate a four-wave mixing signal that contains information on the ?-synuclein in the fluidic sample; and processing the four-wave mixing signal to extract information on the ?-synuclein in the fluidic sample.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: May 17, 2022
    Assignee: SAN DIEGO STATE UNIVERSITY FOUNDATION
    Inventor: William G. Tong
  • Patent number: 11254682
    Abstract: The present disclosure provides novel heteroaryl compounds of formula (IV). Such compounds are useful for the treatment of cancers.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: February 22, 2022
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Jianming Zhang, Barun Okram, Xianming Deng, Jae Won Chang, Amy Wojciechowski
  • Patent number: 11040975
    Abstract: The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: June 22, 2021
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Francois-Rene Alexandre, Rachid Rahali, Izzat Raheem, Christophe Parsy
  • Patent number: 10758536
    Abstract: The present application discloses a method of treating a Varicella-Zoster Virus (VZV) infection in an individual in need thereof, including the step of administering to said individual an effective Varicella-Zoster Virus antiviral amount of a compound called N-methanocarbathymidine (N-MCT), which has a northern configuration with the structure as follows
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: September 1, 2020
    Assignee: L & J Bio Inc
    Inventors: Jennifer Moffat, Dongmei Liu, Wanda Coombs, Michael Appel, Aquilur Rahman
  • Patent number: 10322103
    Abstract: The present invention, in one or more embodiments, comprises derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecyl catechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising urushiol esters of general formula (IA) [Formula should be entered here] tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a formulation containing at least one urushiol ester compound.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: June 18, 2019
    Assignee: UNIVERSITY OF MISSISSIPPI
    Inventors: Mahmoud Elsohly, Waseem Gul, Mohammad Khalid Ashfaq
  • Patent number: 10280167
    Abstract: The present invention relates to purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: May 7, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jean-François Bonfanti, Frédéric Marc Maurice Doublet, Werner Embrechts, Jérôme Michel Claude Fortin, David Craig McGowan, Philippe Muller, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 10189841
    Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3?, R4, R5, X1, X2, X3, X4, and n are described herein.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 29, 2019
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin A. Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
  • Patent number: 9556176
    Abstract: The present invention relates to purine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: January 31, 2017
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: Jean-François Bonfanti, Frédéric Marc Maurice Doublet, Werner Embrechts, Jérôme Michel Claude Fortin, David Craig McGowan, Philippe Muller, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 9408849
    Abstract: The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: August 9, 2016
    Assignee: Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory
    Inventors: Deping Yi, Zhike Tian, Weidong Ye
  • Publication number: 20150148307
    Abstract: The present invention is directed to methods of prognosing relapsed leukemia in a subject. These methods are based on the detection of one or more relapse-specific gene mutations in a patient sample. The present invention further relates to methods of preventing and treating relapse leukemia in a subject based on the determined prognosis of the subject.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 28, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: William L. Carroll, Julia A. Meyer
  • Publication number: 20150110869
    Abstract: The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infections, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutical composition comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and, optionally, a moisture barrier coating. A method of manufacturing an adhesive-free pharmaceutical composition is also disclosed.
    Type: Application
    Filed: May 28, 2013
    Publication date: April 23, 2015
    Inventors: Mathew Philip, Naresh Talwar
  • Publication number: 20150098909
    Abstract: A soluble fiber lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and one or more additives dispersed in the soluble-fiber matrix. In some cases, a soluble fiber lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in soluble fiber lozenge provided herein can include maltodextrin. The soluble fiber lozenge is adapted to release one or more additives from the body when the body is received within the oral cavity of a consumer and exposed to saliva. A method of making soluble fiber lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, one or more additives, and less than 15 weight percent water while maintaining a mixture temperature of less than 200° C. and portioning the molten mixture into a plurality of soluble fiber lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Shuzhong Zhuang, Phillip M. Hulan, William J. Burke, Gerd Kobal
  • Publication number: 20150079157
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt as an active ingredient. And also, the present invention provides a cosmetic composition for improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt; and a food (i.e., a functional food) for preventing or improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 19, 2015
    Applicant: DAEWOONG CO., LTD.
    Inventors: Gyeong-Sug Nam, Se-Joon Yoon, Ok-Gyung Choi, Jin-Pyo Kim, Soo-Jin Choi, Hyong-Jin Park
  • Publication number: 20150079116
    Abstract: NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 19, 2015
    Inventors: Jonathan Braun, Lin Lin
  • Patent number: 8969362
    Abstract: The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: March 3, 2015
    Assignees: AstraZeneca Aktiebolag, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
  • Patent number: 8969361
    Abstract: Cyclopropanecarboxylate esters of purine analogues, method of making and using the same for treating herpes virus infections and tumors are disclosed.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: March 3, 2015
    Assignee: Annji Pharmaceutical Co., Ltd.
    Inventors: Ji-Wang Chern, Shin-Yu Lai, Pei-Teh Chang
  • Patent number: 8946242
    Abstract: Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: February 3, 2015
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Chung K. Chu
  • Patent number: 8921384
    Abstract: Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: December 30, 2014
    Assignee: Unversity of Georgia Research Foundation, Inc.
    Inventor: Chung K. Chu
  • Publication number: 20140378446
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 30, 2013
    Publication date: December 25, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury, Yan Shunqi, Longcheng Wang, Leah Lynn Frye
  • Publication number: 20140315930
    Abstract: The present invention is directed to fast release pharmaceutical compositions comprising entecavir or its pharmaceutically acceptable salts, process for preparing the same and use of such compositions for the treatment of Hepatitis B virus infection.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 23, 2014
    Applicant: Hetero Research Foundation
    Inventors: Bandi Parthasaradhi Reddy, Podili Khadgapathi, Nelluri Ramarao
  • Publication number: 20140303112
    Abstract: The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.
    Type: Application
    Filed: April 9, 2013
    Publication date: October 9, 2014
    Inventors: Han-Min CHEN, Cheng-Yi KUO, Chun-Fang HUANG, Jiun-Tsai LIN
  • Publication number: 20140296264
    Abstract: A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.
    Type: Application
    Filed: June 12, 2014
    Publication date: October 2, 2014
    Inventor: Lili Liu
  • Patent number: 8846697
    Abstract: The present invention provides purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: September 30, 2014
    Assignee: The Regents of the University of California
    Inventors: Dennis A. Carson, Howard B. Cottam, Guangyi Jin, Christina C. N. Wu, Suzanne Grimshaw
  • Publication number: 20140271772
    Abstract: The present invention relates to a biodegradable implantable drug delivery device comprising a biodegradable polymeric material in combination with a therapeutic compound effective for the treatment of a member of the herpesvirus family, wherein the biodegradable implantable drug delivery device is fabricated by a novel method that provides for increased homogeneity and dispersity of the therapeutic compound impregnated within the biodegradable polymeric material.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 18, 2014
    Inventors: BARRY J. MARGULIES, JILL K. BADIN, SOGAND FARTASH-NAINI, THAMAR ETIENNE, SARAH FARGIS, AMANDEEP SAMRA
  • Publication number: 20140243282
    Abstract: The present invention relates to novel drug conjugates, where in two drugs are linked together through an appropriate linker having at least two functional groups capable of forming covalent bond with drugs D1 and D2. The invention also relates to developing novel compositions, methods for their preparation and their use in treating various disease conditions.
    Type: Application
    Filed: December 12, 2011
    Publication date: August 28, 2014
    Inventor: Satish Reddy Kallam
  • Publication number: 20140242108
    Abstract: A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II:
    Type: Application
    Filed: February 22, 2013
    Publication date: August 28, 2014
    Applicant: CAYLA
    Inventors: Thierry LIOUX, Daniel DROCOURT, Fabienne VERNEJOUL, Gerard TIRABY, Eric PEROUZEL
  • Patent number: 8796292
    Abstract: The invention features compounds of formula (I): The compounds are useful as antibacterial agents, especially again Clostridium difficile-associated diseases.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: August 5, 2014
    Assignee: GLSynthesis Inc.
    Inventors: George E. Wright, Wei-Chu Xu
  • Patent number: 8796291
    Abstract: Disclosed are A3 adenosine receptor antagonists and/or partial agonists of formula (I): wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The antagonists or partial agonists find use in treating a number of diseases including cancer, glaucoma, inflammatory diseases, asthma, stroke, myocardial infarction, allergic reactions, rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis, brain arteriole diameter constriction, bronchoconstriction, and myocardial ischemia, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: August 5, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kenneth A. Jacobson, Artem Melman, Ben Bih-Ren Wang
  • Publication number: 20140213600
    Abstract: The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (HSV), and then administering to the human the compound anti-HSV agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (Neurodermatitis, Prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, Alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, Crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, Parkison's disease, anemia, cytopenia those among the diagnostic criteria.
    Type: Application
    Filed: January 29, 2013
    Publication date: July 31, 2014
    Inventor: Lily Hsiao
  • Patent number: 8790655
    Abstract: The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: July 29, 2014
    Assignee: The Regents of The University of California
    Inventors: Dennis A. Carson, Howard B. Cottam, Wolfgang Wrasidlo, Christina C. N. Wu, Gregory A. Daniels
  • Patent number: 8771712
    Abstract: The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a acyclovir compound. Methods of treatment, and methods of preparing the topical composition are also provided.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: July 8, 2014
    Assignee: Emisphere Technologies, Inc.
    Inventors: Steven Dinh, Puchun Liu, Ihor Shevchuk
  • Publication number: 20140179665
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: December 9, 2013
    Publication date: June 26, 2014
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Patent number: 8735407
    Abstract: Disclosed are (N)-methanocarba adenine nucleosides, e.g., of formula (I) as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: May 27, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Kenneth A. Jacobson, Artem Melman
  • Patent number: 8703942
    Abstract: The present disclosure provides inhibitors of Hsp90 and methods of making and using the same. Such compounds are useful as radioimaging ligands and for the treatment of cancer and other conditions where cell growth or maintenance depend on Hsp90 activity.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: April 22, 2014
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gabriela Chiosis, Huazhong He, Laura Llauger-Bufi, Joungnam Kim, Steve M. Larson, Peter Smith-Jones
  • Publication number: 20140107098
    Abstract: Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 17, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Bryan James Branstetter, J. Guy Breitenbucher, Alec D. Lebsack, Jing Liu, Jason C. Rech, Wei Xiao
  • Publication number: 20140088121
    Abstract: The disclosure relates to Compounds of Formulae (IA) and (IB): and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Xd, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (IA) and/or (IB), and methods to treat or prevent a condition, such cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (IA) or (IB). The disclosure further relates to compounds of Formulae (IA) and IB) in which X2 is a leaving for introducing a radiolabeled atom, such as 124I or 131I and to methods of using such compounds in the preparation of radiolabeled compounds, particularly for use in imaging.
    Type: Application
    Filed: April 5, 2012
    Publication date: March 27, 2014
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Weilin Sun, Tony Taldone, Pallav Patel, Gabriela Chiosis
  • Patent number: 8673926
    Abstract: Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: March 18, 2014
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Chung K. Chu
  • Patent number: 8637527
    Abstract: Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: January 28, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bryan James Branstetter, J. Guy Breitenbucher, Alec D. Lebsack, Jing Liu, Jason C Rech, Wei Xiao
  • Publication number: 20140005147
    Abstract: A topical composition containing a DNA polymerase inhibitor for removing hair as well as methods of inducing hair loss is described.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventor: Carmela VITTORIO
  • Publication number: 20130331384
    Abstract: The disclosure provides for novel antimicrobial agents, methods of making, and methods of use thereof.
    Type: Application
    Filed: February 14, 2012
    Publication date: December 12, 2013
    Applicant: The Regents of the University of California
    Inventors: Richard L. Gallo, Teruaki Nakatsuji
  • Publication number: 20130330322
    Abstract: A method of reducing the appearance of skin aging comprising the step of applying a topical composition to the skin of a human exhibiting one or more signs of skin aging selected from fine lines, wrinkles, decreased skin elasticity, decreased light reflection, uneven pigmentation (dyschromia), coarse texture, dryness, solar lentigos, seborrheic keratoses, decreased dermal thickness, and/or increased sebum production, wherein the composition consists essentially of a dermatologically acceptable carrier and a targeted immune response modifier selected the group consisting of: (i) a 5-amino thiazolo[4,5-d]pyrimidin-one compound; (ii) an 8-hydroxyadenine compound; (iii) an imidazo-1,5-napthyridine compound; (iv) a 2-substituted-8-oxodeazapurine; (v) methyl 2-(3-{[6-amino-2-butoxy-8-oxo-7H-purin-9(8H)-yl]methyl}phenyl)acetate; (vi) 2-(3-{[6-amino-2-butoxy-8-oxo-7H-purin-9(8H)-yl]methyl}phenyl)acetic acid; and (iii) methyl 2-(3-(((3-(6-amino-2-butoxy-8-oxo-7H-purin-9(8H)-yl)propyl)(3-(dimethylamino)propyl)amino) ph
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Metabeauty, Inc.
    Inventor: Leslie Baumann
  • Publication number: 20130281470
    Abstract: A method of treatment of: i) HIV-1 infections in mammals, including humans; or ii) HBV infections in mammals, including humans; which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A) or a pharmaceutically acceptable salt thereof; and compounds for use in the method.
    Type: Application
    Filed: June 19, 2013
    Publication date: October 24, 2013
    Applicant: Novartis AG
    Inventors: Richard Anthony Vere Hodge, Raymond Schinazi
  • Publication number: 20130236504
    Abstract: Disclosed are delivery systems that can be used for treating cancer. The delivery systems include a delivery vehicle in conjunction with a chemo-adjuvant. The chemo-adjuvant can enhance the efficacy of a therapeutic agent that can be delivered in conjunction with the delivery vehicle or can be delivered independently of the delivery vehicle.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 12, 2013
    Applicants: Medical University of South Carolina, Clemson University
    Inventors: Frank Alexis, Bruce Frankel
  • Publication number: 20130210826
    Abstract: The present invention features methods and compositions for preventing, reducing, or treating a traumatic, metabolic, or toxic peripheral nerve lesion or pain including neuropathic pain, inflammatory, and nociceptive pain by administering to a mammal a compound that reduces expression or activity of BH4. This reduction may be achieved by reducing activity of a BH4 synthetic enzyme, including GTP cyclohydrolase, sepiapterin reductase, or dihydropteridine reductase; antagonizing the cofactor function of BH4 or BH4-dependent enzymes; or blocking BH4 binding to membrane bound receptors. The invention provides methods for diagnosing pain or a peripheral nerve lesion in a mammal by measuring levels of BH4 or its metabolites in biological sample or the levels or activity of any one of the BH4 synthetic enzyme in tissue samples of a mammal.
    Type: Application
    Filed: October 11, 2012
    Publication date: August 15, 2013
    Applicant: The General Hospital Corporation
    Inventor: The General Hospital Corporation
  • Patent number: 8507507
    Abstract: The present application includes novel modulators of TLRs, compositions containing such compounds, therapeutic methods that include the administration of such compounds.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: August 13, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Randall L. Halcomb, Paul A. Roethle
  • Publication number: 20130197014
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: April 30, 2012
    Publication date: August 1, 2013
    Applicant: Pharmacyclics, Inc.
    Inventors: Wei CHEN, David J. LOURY
  • Patent number: 8476285
    Abstract: The invention relates to compounds of Formulae I-III: and therapeutic uses thereof, wherein A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group; B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group; R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo; and L1, L2, are as defined herein.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: July 2, 2013
    Assignee: Myrexis, Inc.
    Inventors: Ashok C. Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko
  • Publication number: 20130165455
    Abstract: The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.
    Type: Application
    Filed: November 20, 2012
    Publication date: June 27, 2013
    Applicant: The Regents of The University of California
    Inventors: Dennis A. Carson, Howard B. Cottam, Michael Chan, Christina C.N. Wu, Suzanne Grimshaw
  • Publication number: 20130157973
    Abstract: Methods of treating gastrointestinal disorders, in a patient in need thereof, including disorders of the liver and pancreas, using an amount of an orally dosed TLR-7 compound in an amount sufficient to increase IFN in the gastrointestinal area, including the liver, but not significantly increasing systemic IFN.
    Type: Application
    Filed: December 19, 2012
    Publication date: June 20, 2013
    Applicant: Gilead Sciences, Inc.
    Inventor: Gilead Sciences, Inc.
  • Publication number: 20130137694
    Abstract: There is provided modulators of Nrf2 protein which comprises a compound which binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2. There is also provided pharmaceutical compositions containing the modulators, as well as uses and method of use of the modulators for the treatment of conditions.
    Type: Application
    Filed: May 31, 2011
    Publication date: May 30, 2013
    Inventors: Gerald Batist, Jian Hui Wu